From clearance to capital: regulatory timing, financing conditions, and observability limits in medical-device commercialization

An authorized medical device may still need outside capital before its sponsor, the firm responsible for it, can manufacture and launch it. The paper asks what public U.S. records can show about whether authorization timing relates to access to that capital, and what a credible test needs. It does not estimate a financing or commercialization effect. The data combine 52,910 successful authorizations for submissions received in 2008–2024, a monthly capital-market measure, and a prototype match of 510(k) applicant names to Form D notices of private securities offerings. Among submissions received through 2022, the longest tenth accounts for 49.4–57.4 percent of days above the pathway median. Receipt-to-decision durations include applicant-response periods and do not measure unexpected or agency-caused delay. The market measure takes similar values in neighboring months. Its nine high periods, runs of two or more high months, last two to nine months; its relevance to individual sponsors is untested. As an observability diagnostic, the Form D prototype shows how name linkage can mislead. Records in the longest-duration quartile less often have a notice within a year (2.1 versus 3.1 percent in the shortest). Their applicant names, however, also appear less often among issuers (8.7 versus 14.4 percent), and among records with a name found, the notice share is not lower. About 11 percent of outcome windows are incomplete, and amendments count as notices. The contribution is to document these measurement requirements and to specify a sponsor-level test with validated identities, decision-date forecasts at receipt, and dated capital events.